You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

~ Buy the OJJAARA (momelotinib dihydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

OJJAARA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Ojjaara patents expire, and when can generic versions of Ojjaara launch?

Ojjaara is a drug marketed by Glaxosmithkline and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and three patent family members in thirty-five countries.

The generic ingredient in OJJAARA is momelotinib dihydrochloride. One supplier is listed for this compound. Additional details are available on the momelotinib dihydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Ojjaara

Ojjaara will be eligible for patent challenges on September 15, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 15, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OJJAARA?
  • What are the global sales for OJJAARA?
  • What is Average Wholesale Price for OJJAARA?
Summary for OJJAARA
International Patents:103
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 1
Drug Prices: Drug price information for OJJAARA
What excipients (inactive ingredients) are in OJJAARA?OJJAARA excipients list
DailyMed Link:OJJAARA at DailyMed
Drug patent expirations by year for OJJAARA
Drug Prices for OJJAARA

See drug prices for OJJAARA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OJJAARA
Generic Entry Date for OJJAARA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OJJAARA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Karyopharm Therapeutics IncPhase 2

See all OJJAARA clinical trials

Pharmacology for OJJAARA

US Patents and Regulatory Information for OJJAARA

OJJAARA is protected by four US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OJJAARA is ⤷  Sign Up.

This potential generic entry date is based on TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting OJJAARA


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF LESS THAN 50 BILLION/L

Phenyl amino pyrimidine compounds and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

FDA Regulatory Exclusivity protecting OJJAARA

TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA
Exclusivity Expiration: ⤷  Sign Up

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline OJJAARA momelotinib dihydrochloride TABLET;ORAL 216873-001 Sep 15, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline OJJAARA momelotinib dihydrochloride TABLET;ORAL 216873-003 Sep 15, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline OJJAARA momelotinib dihydrochloride TABLET;ORAL 216873-002 Sep 15, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OJJAARA

See the table below for patents covering OJJAARA around the world.

Country Patent Number Title Estimated Expiration
Philippines 12016502461 N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE HYDROCHLORIDE SALTS ⤷  Sign Up
Taiwan 202012378 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide ⤷  Sign Up
Costa Rica 20160575 SALES DEL CLORHIDRATO DE N-(CIANOMETIL)-4-(2-(4-MORFOLINOFENILAMINO) PIRIMIDIN-4-IL)BENZAMIDA ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.